Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00442780
Status:
COMPLETED
Last Update Posted:
2009-01-09
First Post:
2007-03-01
Brief Title:
Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinsons Disease
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MOBILE
Brief Summary:
The main purpose of this study is to determine the safety of BIIB014 and how well BIIB014 is tolerated when given at different doses to patients with early-stage Parkinsons Disease
This study will also explore
How BIIB014 is affected when given to patients with early-stage Parkinsons Disease this will be done by measuring the levels of BIIB014 in the blood at several different times during the study and
The activity of BIIB014 when given to early Parkinsons patients this will be done by performing different Parkinsons Disease assessments and other tests during the study
Patients who enter this study will be randomly assigned to receive either BIIB014 or a placebo but because the study is blinded neither they nor their study doctor will know which study treatment they are taking
This study will also explore
How BIIB014 is affected when given to patients with early-stage Parkinsons Disease this will be done by measuring the levels of BIIB014 in the blood at several different times during the study and
The activity of BIIB014 when given to early Parkinsons patients this will be done by performing different Parkinsons Disease assessments and other tests during the study
Patients who enter this study will be randomly assigned to receive either BIIB014 or a placebo but because the study is blinded neither they nor their study doctor will know which study treatment they are taking
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRA CT NO 2007-000398-47 | None | None | None |